Доказательная кардиология

DiMatteo M.R. Variations in patients’ adherence to medical recommendations: a quantitative review of 50 years of research. Med Care 2004;42:200-209.

Miller N.H., Hill M., Kottke T., Ockene I.S. The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation 1997;95:1085-1090.

Morris L.S., Schulz R.M. Patient compliance - an overview. J Clin Pharm Ther 1992;17:283-295.

Donovan J.L. Patient decision making. The missing ingredient in compliance research. Int J Technol Assess Health Care 1995;11:443-455.

Ellis S., Shumaker S., Sieber W., Rand C. Adherence to pharmacological interventions. Current trends and future directions. The Pharmacological Intervention Working Group. Control Clin Trials 2000;21:S218-225.

Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-497.

DiMatteo M.R., Giordani P.J., Lepper H.S., Croghan T.W. Patient adherence and medical treatment outcomes: a meta-analysis. Med Care 2002;40:794-811.

Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med 1980;303:1038-1041.

Horwitz R.I., Viscoli C.M., Berkman L. et al. Treatment adherence and risk of death after a myocardial infarction. Lancet 1990;336:542-545.

Gallagher E.J., Viscoli C.M., Horwitz R.I. The relationship of treatment adherence to the risk of death after myocardial infarction in women. Journal of the American Medical Association 1993;270:742-744.

Czajkowski S.M., Chesney M.A., Smith A.W. Adherence and the placebo effect. In: Shumaker S.A., Schron E.B., Ockene J.K., eds. The handbook of health behavior change. New York: Springer, 1990:515-534.

Obias-Manno D., Friedmann E., Brooks M.M. et al. Adherence and arrhythmic mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Annals of Epidemiology 1996;6:93-101.

McDermott M.M., Schmitt B., Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch Intern Med 1997;157:1921-1929.

Hays R.D., Kravitz R.L., Mazel R.M., Sherbourne C.D., DiMatteo M.R., Rogers W.H. et al. The impact of patient adherence on health outcomes for patients with chronic disease in the medical outcomes study. J Behav Med 1994;17:347-360.

Irvine J., Baker B., Smith J. et al. Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Psychosomatic Medicine 1999;61:566-575.

Glynn R.J., Buring J.E., Manson J.E. et al. Adherence to aspirin in the prevention of myocardial infarction. The Physicians’ Health Study. Archives of Internal Medicine 1994;154:2649-2657.

Shepherd J., Cobbe S.M., Lorimer A.R. et al. Compliance and adverse event withdrawal: Their impact on the West of Scotland Coronary Prevention Study. European Heart Journal 1997;18:1718-1724.

Cornfield J. The University Group Diabetes Program. A further statistical analysis of the mortality findings. Journal of the American Medical Association 1971;217:1676-1687.

Meinert C.L., Knatterud G.L., Prout T.E., Klimt C.R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970;19:789-830.

Wei L., Wang J., Thompson P. et al. Adherence to statin treatment and readmission of patients after myocardial infarction: a six year follow up study. Heart 2002;88:229-233.

Cotter G., Shemesh E., Zehavi M. et al. Lack of aspirin effect: Aspirin resistance or resistance to taking aspirin? American Heart Journal 2004;147:293-300.

Wei L., Flynn R., Murray G.D., McDonald T.M. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: Who is not getting the treatment? Pharmacoepidemiology & Drug Safety 2004;13:761-766.

San Andres Rebollo F.J., Rubio Garcia R., Castilla Catalan J. et al. Mortality and survival in a cohort of 1,115 HIV-infected patients (1989-97). Anales de Medicina Interna 2004;21:523-532.

Cohn S.E., Kammann E., Williams P. et al. Association of adherence to Mycobacterium avium complex prophylaxis and antiretroviral therapy with clinical outcomes in acquired immunodeficiency syndrome. Clinical Infectious Diseases 2002;34:1129-1136.

Garcia de Olalla P., Knobel H., Carmona A. et al. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2002;30:105-110.

Grimwade K., Sturm A.W., Nunn A.J. et al. Effectiveness of cotrimoxazole prophylaxis on mortality in adults with tuberculosis in rural South Africa. AIDS 2005;19:163-168.

Hogg R.S., Heath K., Bangsberg D. et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002;16:1051-1058.

Paterson D.L., Swindells S., Mohr J. et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine 2000;133:21-30.

Wood E., Hogg R.S., Yip B. et al. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4(+) cell count is 0.200 to 0.350 X 10(9) cells/L. Annals of Internal Medicine 2003;139:810-816.

Howell N., Trotter R., Mottram D.R., Rowe D. Compliance with statins in primary care. Pharmaceutical Journal 2004;272:23-26.

Miura T., Kojima R., Mizutani M. et al. Effect of digoxin noncompliance on hospitalization and mortality in patients with heart failure in long-term therapy: A prospective cohort study. European Journal of Clinical Pharmacology 2001;57:77-83.

Dobbels F., De Geest S., Van Cleemput J. et al. Effect of late medication non-compliance on outcome after heart transplantation: A 5-year follow-up. Journal of Heart and Lung Transplantation 2004;23:1245-1251.

Echt D.S., Liebson P.R., Mitchell L.B. et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med 1991;324:781-788.

In: Higgins J.P.T., Green S., eds. Cochrane handbook for systematic reviews of interventions 4.2.5 [updated May 2005]. www.cochrane.dk/cochrane/handbook/hbook.htm (accessed 3 Apr 2006).

Tobias A. Assessing the influences of a single study in meta-analysis. Stata Tech Bull 1999;47:15-17.

Moher D., Schulz K.F., Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285:1987-1991.

Boudes P. Drug compliance in therapeutic trials: a review. Control Clin Trials 1998;19:257-268.

Haynes R.B., Dantes R. Patient compliance and the conduct and interpretation of therapeutic trials. Control Clin Trials 1987;8:12-19.

Efron B., Feldman D. Compliance as an explanatory variable in clinical trials. J Am Stat Assoc 1991;86:9-26.

Chewning B. The healthy adherer and the placebo effect. BMJ 2006 1;333:18-19.

Beecher H.K. The powerful placebo. JAMA 1955;159:1602-1606.

Barrett B., Muller D., Rakel D. et al. Placebo, meaning, and health. Perspect Biol Med 2006;49:178-198.

Pfeffer M.A., Swedberg K., Granger C.B. et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-766.

Granger B.B., Swedberg K., Ekman I. et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005;366:2005-2011.